Identification

Name
Tiapride
Accession Number
DB13025
Type
Small Molecule
Groups
Approved, Investigational
Description

Tiapride is a drug that selectively blocks D2 and D3 dopamine receptors in the brain.

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Tiapride hydrochloride25N106WEDO51012-33-0OTFDPNXIVHBTKW-UHFFFAOYSA-N
International/Other Brands
Gramalil / Italprid / Luxoben / Sereprile / Tiapridal
Categories
UNII
LAH70H9JPH
CAS number
51012-32-9
Weight
Average: 328.427
Monoisotopic: 328.145677956
Chemical Formula
C15H24N2O4S
InChI Key
JTVPZMFULRWINT-UHFFFAOYSA-N
InChI
InChI=1S/C15H24N2O4S/c1-5-17(6-2)10-9-16-15(18)13-11-12(22(4,19)20)7-8-14(13)21-3/h7-8,11H,5-6,9-10H2,1-4H3,(H,16,18)
IUPAC Name
N-[2-(diethylamino)ethyl]-5-methanesulfonyl-2-methoxybenzene-1-carboximidic acid
SMILES
CCN(CC)CCN=C(O)C1=C(OC)C=CC(=C1)S(C)(=O)=O

Pharmacology

Indication

Tiapride is indicated for the treatment of a variety of neurological and psychiatric disorders including dyskinesia, alcohol withdrawal syndrome, negative symptoms of psychosis, and agitation and aggression in the elderly.

Structured Indications
Not Available
Pharmacodynamics

Tiapride displays a relatively high regional selectivity for limbic areas. One study found that, in contrast with haloperidol, which displays equal affinity for receptors in the rat limbic system and striatum, tiapride shows over three times as much affinity for limbic areas than striatal areas. Another study in rats found tiapride's affinity for the septum, a limbic region, to be over thirty times as high as for the striatum. Efficacy at the D2 receptor is moderate, with 80 percent of receptors occupied even in the presence of excess tiapride concentrations.

Mechanism of action

Tiapride is a dopamine D2 and D3 receptor antagonist. It is more selective than other neuroleptic drugs such as haloperidol and risperidone, which not only target four of the five known dopamine receptor subtypes (D1-4), but also block serotonin (5-HT2A, 2C), α1- and α2-adrenergic, and histamine H1 receptors. Compared to these drugs, tiapride has a relatively moderate affinity for its target receptors, displacing 50 percent of 3H-raclopride binding at a concentration of 320 nM at D2 receptors and a concentration of 180 nM at D3 receptors.

TargetActionsOrganism
AD(2) dopamine receptor
blocker
Human
AD(3) dopamine receptor
blocker
Human
ASerotonin Receptors
antagonist
Human
AAlpha-1 adrenergic receptors
antagonist
Human
AAlpha-2 adrenergic receptors
antagonist
Human
AHistamine H1 receptor
antagonist
Human
Absorption

The bioavailability of tiapride is approximately 75 percent. Peak plasma concentrations are attained between 0.4 and 1.5 hours following administration, and steady-state concentrations achieved 24 to 48 hours after beginning administration 3 times a day. Benzamide and its derivatives are highly water-soluble, and because of their polarity are believed to cross the blood–brain barrier via carrier-mediated transport.

Volume of distribution

Tiapride distributes rapidly and exhibits virtually no binding to plasma proteins, giving it a relatively high volume of distribution

Protein binding

Negligible

Metabolism

Tiapride is minimally metabolized in humans, 70 % of the drug is eliminated in unchanged form in the urine within 24 hours. Only low concentration of N-desethyl tiapride and tiapride N-oxide and no phase II metabolites were detected.

Route of elimination

Urine (70% as unchanged tiapride)

Half life

2.9–3.6 hours

Clearance

16.6 l/h.

Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineTiapride may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineTiapride may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineTiapride may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Tiapride.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Tiapride.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Tiapride.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Tiapride.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Tiapride.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Tiapride is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Tiapride.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Tiapride.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Tiapride.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Tiapride.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Tiapride.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Tiapride is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tiapride.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Tiapride is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Tiapride.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Tiapride is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Tiapride.Experimental
AmphetamineTiapride may decrease the stimulatory activities of Amphetamine.Approved, Illicit
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Tiapride.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Tiapride.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Tiapride.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Tiapride.Investigational, Vet Approved
AzelastineTiapride may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Tiapride is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Tiapride.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Tiapride.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Tiapride.Approved
BenzphetamineTiapride may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Tiapride.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Tiapride is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tiapride.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tiapride.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Tiapride is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tiapride.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Tiapride.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Tiapride is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Tiapride.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Tiapride.Approved, Investigational
BuprenorphineTiapride may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Tiapride.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Tiapride.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Tiapride.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Tiapride is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Tiapride.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Tiapride.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Tiapride.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Tiapride.Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Tiapride.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Tiapride.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Tiapride is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Tiapride.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Tiapride is combined with Carisoprodol.Approved
CetirizineThe risk or severity of adverse effects can be increased when Tiapride is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Tiapride.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Tiapride.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Tiapride.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Tiapride.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Tiapride is combined with Chlorphenamine.Approved
ChlorphentermineTiapride may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Tiapride.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Tiapride.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Tiapride is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Tiapride.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Tiapride.Approved
ClemastineThe risk or severity of adverse effects can be increased when Tiapride is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Tiapride is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Tiapride is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Tiapride.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Tiapride is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Tiapride is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Tiapride is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Tiapride is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tiapride.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Tiapride is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Tiapride.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Tiapride.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Tiapride.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Tiapride is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tiapride.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Tiapride is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Tiapride is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tiapride.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Tiapride is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Tiapride.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Tiapride.Approved
DesipramineThe risk or severity of adverse effects can be increased when Tiapride is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Tiapride is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Tiapride.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Tiapride.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Tiapride is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Tiapride.Approved, Vet Approved
DextroamphetamineTiapride may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Tiapride.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Tiapride.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tiapride.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Tiapride.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Tiapride.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Tiapride is combined with Diethyl ether.Experimental
DiethylpropionTiapride may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Tiapride is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tiapride.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Tiapride.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Tiapride.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tiapride.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Tiapride is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tiapride.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tiapride.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Tiapride is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Tiapride.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Tiapride is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Tiapride.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Tiapride.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Tiapride.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tiapride.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Tiapride.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Tiapride.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tiapride.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Tiapride.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Tiapride.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Tiapride is combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Tiapride.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Tiapride.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Tiapride.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Tiapride is combined with Entacapone.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Tiapride.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Tiapride.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Tiapride.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Tiapride.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Tiapride.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Tiapride.Approved
EthanolTiapride may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tiapride.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Tiapride is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Tiapride is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tiapride.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Tiapride is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Tiapride.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Tiapride.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Tiapride.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Tiapride.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Tiapride.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Tiapride.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Tiapride is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Tiapride.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Tiapride is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Tiapride is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Tiapride.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tiapride.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Tiapride is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Tiapride is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Tiapride is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Tiapride.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Tiapride is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Tiapride.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Tiapride.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Tiapride.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Tiapride.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Tiapride.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Tiapride.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Tiapride is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Tiapride.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Tiapride is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Tiapride.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Tiapride.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tiapride.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Tiapride is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Tiapride.Approved, Illicit, Investigational
GepefrineTiapride may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Tiapride.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Tiapride.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Tiapride is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Tiapride.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Tiapride.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Tiapride.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Tiapride.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Tiapride.Approved
HydrocodoneTiapride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Tiapride.Approved, Illicit
HydroxyamphetamineTiapride may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tiapride.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Tiapride is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Tiapride is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Tiapride is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Tiapride.Investigational
Iofetamine I-123Tiapride may decrease the stimulatory activities of Iofetamine I-123.Approved
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Tiapride.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Tiapride.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Tiapride.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Tiapride.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Tiapride.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Tiapride is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Tiapride is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Tiapride.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Tiapride is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Tiapride is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Tiapride is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Tiapride.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Tiapride.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Tiapride.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Tiapride.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Tiapride.Approved, Investigational
LisdexamfetamineTiapride may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Tiapride.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Tiapride.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Tiapride is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Tiapride is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Tiapride.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Tiapride.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Tiapride is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Tiapride.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Tiapride.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tiapride.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Tiapride is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Tiapride is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Tiapride is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Tiapride is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Tiapride.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Tiapride.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Tiapride.Approved, Investigational
MephedroneTiapride may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineTiapride may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tiapride.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tiapride.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Tiapride is combined with Meptazinol.Experimental
MequitazineTiapride may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Tiapride.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Tiapride is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Tiapride.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Tiapride.Approved, Illicit
MethamphetamineTiapride may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Tiapride.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Tiapride.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Tiapride is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Tiapride.Approved
MethotrimeprazineTiapride may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Tiapride.Approved, Investigational, Vet Approved
MethoxyphenamineTiapride may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Tiapride is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Tiapride.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Tiapride is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Tiapride.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Tiapride.Approved, Investigational
MetyrosineTiapride may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Tiapride.Approved, Illicit
MidomafetamineTiapride may decrease the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Tiapride.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tiapride.Approved, Investigational
MirtazapineTiapride may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDATiapride may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Tiapride.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Tiapride.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Tiapride.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Tiapride.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Tiapride.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Tiapride.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Tiapride.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Tiapride.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Tiapride.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Tiapride is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Tiapride.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Tiapride is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Tiapride.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Tiapride is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Tiapride.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Tiapride.Approved, Illicit
OrphenadrineTiapride may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Tiapride.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Tiapride.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Oxethazaine is combined with Tiapride.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Tiapride.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Tiapride.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tiapride.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Tiapride.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Tiapride.Approved
ParaldehydeTiapride may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Tiapride.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Tiapride is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tiapride.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Tiapride.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Tiapride.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Tiapride.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Tiapride.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Tiapride.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Tiapride.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Tiapride is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Tiapride.Approved
PhenibutThe risk or severity of adverse effects can be increased when Tiapride is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Tiapride.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Tiapride is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Tiapride.Approved
PhentermineTiapride may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Tiapride is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Tiapride.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Tiapride.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Tiapride is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Tiapride.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Tiapride is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Tiapride is combined with Pomalidomide.Approved
PramipexoleTiapride may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Tiapride.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Tiapride.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Tiapride.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Tiapride.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Tiapride is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Tiapride.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Tiapride.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tiapride.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Tiapride.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Tiapride is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Tiapride is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Tiapride.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Tiapride.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Tiapride.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Tiapride is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Tiapride is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Tiapride.Investigational
PseudoephedrineTiapride may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Tiapride.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tiapride.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Tiapride.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Tiapride is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Tiapride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Tiapride is combined with Ramelteon.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Tiapride.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tiapride.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Tiapride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Tiapride.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Tiapride.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Tiapride.Investigational
RitobegronTiapride may decrease the stimulatory activities of Ritobegron.Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Tiapride.Approved
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Tiapride.Vet Approved
RopiniroleTiapride may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Tiapride.Approved
RotigotineTiapride may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Tiapride.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Tiapride is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tiapride.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Tiapride.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Sepranolone is combined with Tiapride.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Tiapride.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Tiapride.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tiapride.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Tiapride.Approved
StiripentolThe risk or severity of adverse effects can be increased when Tiapride is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tiapride.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Tiapride is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Tiapride.Approved, Investigational
SuvorexantTiapride may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Tiapride.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Tiapride.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tiapride is combined with Tasimelteon.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Tiapride.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Tiapride.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Tiapride.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Tiapride.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Tiapride.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Tiapride.Investigational
ThalidomideTiapride may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Tiapride.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Tiapride.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Tiapride.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Tiapride.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiapride is combined with Tiagabine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Tiapride.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tiapride is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Tiapride is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tiapride is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Tiapride is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Tiapride.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Tiapride.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tiapride.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Tiapride.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Tiapride.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Tiapride.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Tiapride is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tiapride.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Tiapride is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Tiapride.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Tiapride is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Tiapride is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Tiapride.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Tiapride.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Tiapride.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Tiapride is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Tiapride.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Tiapride is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Tiapride.Approved
XenonThe risk or severity of adverse effects can be increased when Tiapride is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Tiapride.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Tiapride.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Tiapride is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Tiapride is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Tiapride.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Tiapride.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Tiapride.Approved, Investigational
ZolpidemTiapride may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Tiapride is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Tiapride.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Tiapride.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tiapride.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Scatton B, Cohen C, Perrault G, Oblin A, Claustre Y, Schoemaker H, Sanger DJ, Rouquier L, Porsolt R: The preclinical pharmacologic profile of tiapride. Eur Psychiatry. 2001 Jan;16 Suppl 1:29s-34s. [PubMed:11520476]
  2. Dose M, Lange HW: The benzamide tiapride: treatment of extrapyramidal motor and other clinical syndromes. Pharmacopsychiatry. 2000 Jan;33(1):19-27. [PubMed:10721880]
  3. Bischoff S, Bittiger H, Delini-Stula A, Ortmann R: Septo-hippocampal system: target for substituted benzamides. Eur J Pharmacol. 1982 Apr 23;79(3-4):225-32. [PubMed:7201401]
  4. Norman T, Chiu E, James RH, Gregory MS: Single oral dose pharmacokinetics of tiapride in patients with Huntington's disease. Eur J Clin Pharmacol. 1987;32(6):583-6. [PubMed:2958291]
External Links
Human Metabolome Database
HMDB42039
KEGG Drug
D08590
PubChem Compound
5467
PubChem Substance
347829159
ChemSpider
5268
BindingDB
82073
ChEBI
94666
ChEMBL
CHEMBL84158
Wikipedia
Tiapride
ATC Codes
N05AL03 — Tiapride

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentChronic Motor or Vocal Tic Disorder / Gilles de la Tourette's Syndrome / Tic Disorders1
3RecruitingTreatmentHuntington's Disease (HD)1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1
3Unknown StatusTreatmentPsychosis Nos/Other1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.139 mg/mLALOGPS
logP1.55ALOGPS
logP0.68ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)6.46ChemAxon
pKa (Strongest Basic)8.17ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area79.2 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity88.54 m3·mol-1ChemAxon
Polarizability35.69 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a4r-2900000000-ce7cf18c3df7664007c3
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a4i-2900000000-f2c792ada2d697b7a343
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a4i-5900000000-660415070e12bcbe4376
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a6r-9700000000-2ce26990c6212c2ed171
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-01t9-9200000000-8d71048d6039798257dd
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-01t9-9000000000-128e0b213532d5c3e6b0
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-004i-0009000000-da514094cabb39732203
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-0091000000-c4544a176e5242fdbb7f
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-0090000000-fb4e4eea413d32fc6219
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-08fr-0190000000-90bc8da6d92687ec2d7c
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-0690000000-37fc0504835723e81e17
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03e9-1930000000-612cdc3e15572ae24953

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzenesulfonyl compounds. These are aromatic compounds containing a benzenesulfonyl group, which consists of a monocyclic benzene moiety that carries a sulfonyl group.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzenesulfonyl compounds
Direct Parent
Benzenesulfonyl compounds
Alternative Parents
Phenoxy compounds / Methoxybenzenes / Anisoles / Alkyl aryl ethers / Sulfones / Trialkylamines / Propargyl-type 1,3-dipolar organic compounds / Carboximidic acids / Organopnictogen compounds / Organic oxides
show 1 more
Substituents
Benzenesulfonyl group / Phenoxy compound / Anisole / Phenol ether / Methoxybenzene / Alkyl aryl ether / Sulfone / Sulfonyl / Tertiary amine / Tertiary aliphatic amine
show 15 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Blocker
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Scatton B, Cohen C, Perrault G, Oblin A, Claustre Y, Schoemaker H, Sanger DJ, Rouquier L, Porsolt R: The preclinical pharmacologic profile of tiapride. Eur Psychiatry. 2001 Jan;16 Suppl 1:29s-34s. [PubMed:11520476]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Blocker
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name
DRD3
Uniprot ID
P35462
Uniprot Name
D(3) dopamine receptor
Molecular Weight
44224.335 Da
References
  1. Scatton B, Cohen C, Perrault G, Oblin A, Claustre Y, Schoemaker H, Sanger DJ, Rouquier L, Porsolt R: The preclinical pharmacologic profile of tiapride. Eur Psychiatry. 2001 Jan;16 Suppl 1:29s-34s. [PubMed:11520476]
Kind
Protein group
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...

Components:
References
  1. Scatton B, Cohen C, Perrault G, Oblin A, Claustre Y, Schoemaker H, Sanger DJ, Rouquier L, Porsolt R: The preclinical pharmacologic profile of tiapride. Eur Psychiatry. 2001 Jan;16 Suppl 1:29s-34s. [PubMed:11520476]
Kind
Protein group
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...

Components:
References
  1. Scatton B, Cohen C, Perrault G, Oblin A, Claustre Y, Schoemaker H, Sanger DJ, Rouquier L, Porsolt R: The preclinical pharmacologic profile of tiapride. Eur Psychiatry. 2001 Jan;16 Suppl 1:29s-34s. [PubMed:11520476]
Kind
Protein group
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...

Components:
References
  1. Scatton B, Cohen C, Perrault G, Oblin A, Claustre Y, Schoemaker H, Sanger DJ, Rouquier L, Porsolt R: The preclinical pharmacologic profile of tiapride. Eur Psychiatry. 2001 Jan;16 Suppl 1:29s-34s. [PubMed:11520476]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Scatton B, Cohen C, Perrault G, Oblin A, Claustre Y, Schoemaker H, Sanger DJ, Rouquier L, Porsolt R: The preclinical pharmacologic profile of tiapride. Eur Psychiatry. 2001 Jan;16 Suppl 1:29s-34s. [PubMed:11520476]

Drug created on October 20, 2016 20:08 / Updated on December 01, 2017 17:35